After establishing that the 60 mg/kg dose of MDI-2517 limits the severity of lung fibrosis in two distinct murine models, we next sought to compare the efficacy of the PAI-1 inhibitor to Nintedanib. The gene discussed is SERPINE1; the disease is pulmonary fibrosis.